Enhanced Beclin-1 and LC3 and reduced SQSTM1/p62 expression by β-asarone attenuated Aβ40 and Aβ42 levels in an in vivo AD model [72]. This evidence concerns the gene MAP1LC3A and Alzheimer disease.